---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-030900"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2026-09-22T20:05:55+00:00"
generated_at: "2026-09-22T20:07:16.328755+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aytu Q4 FY26 revenue up 6.4% to $16.1M; EXXUA launches with 3,323 scripts

## Summary
- Q4 FY26 net revenue $16.1M, +6.4% YoY; EXXUA alone contributed $3.9M in first full quarter.
- EXXUA Q4 prescriptions 3,323, up ~138% from Q3; June hit record 1,261 scripts; shipments ~4,600 units.
- Full-year FY26 revenue $57.6M, down 13.3% YoY, driven by ADHD portfolio decline and Adzenys generic competition.
- FY26 net loss $14.3M ($1.16 loss/share) vs $13.6M loss; Adjusted EBITDA -$3.7M vs +$9.2M prior year.
- Cash $26.3M at June 30, 2026; warrant amendment cut derivative warrant liabilities by $26.4M.

## SEC filing metadata
- accession: 0001437749-26-030900
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2026-09-22T20:05:55+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030900/0001437749-26-030900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030900/aytu20260502_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-030900
- JSON: https://secwatch.observer/filing/0001437749-26-030900.json
- Plain text: https://secwatch.observer/filing/0001437749-26-030900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.